Next Article in Journal
Impact of Adiposity and Fat Distribution, Rather Than Obesity, on Antibodies as an Illustration of Weight-Loss-Independent Exercise Benefits
Previous Article in Journal
Autoimmune Disorders & COVID-19
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicines
Volume 8
Issue 10
10.3390/medicines8100056
medicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses

by
Kunihiko Fukuchi
1,
Takuro Koshikawa
2,
Daisuke Asai
2,3,
Megumi Inomata
4,
Hiroshi Sakagami
5,*,
Hiromu Takemura
2,
Taisei Kanamoto
3,
Hikaru Aimi
6 and
Yuji Kikkawa
7
1
Graduate School of Health Sciences, Showa University, Hatanodai 1-5-8, Shinagawa, Tokyo 142-8555, Japan
2
Department of Microbiology, St. Marianna University School of Medicine, Sugao 2-16-1, Miyamae, Kawasaki 216-8511, Japan
3
Laboratory of Microbiology, Showa Pharmaceutical University, 3-3165 Higashi-Tamagawagakuen, Machida, Tokyo 194-8543, Japan
4
Division of Microbiology, Meikai University School of Dentistry, Keyakidai 1-1, Sakado, Saitama 350-0283, Japan
5
Research Institute of Odontology (M-RIO), Meikai University, Keyakidai 1-1, Sakado, Saitama 350-0283, Japan
6
Research Laboratory, Research and Development Division, Nippon Paper Industries Co., Ltd., 5-21-1 Oji, Kita-ku, Tokyo 114-0002, Japan
7
Chemical Sales Department II, Chemical Sales Division, Nippon Paper Industries Co., Ltd., 4-6 Kandasurugadai, Chiyoda-ku, Tokyo 101-0062, Japan
*
Author to whom correspondence should be addressed.
Medicines 2021, 8(10), 56; https://doi.org/10.3390/medicines8100056
Submission received: 23 August 2021 / Revised: 12 September 2021 / Accepted: 16 September 2021 / Published: 3 October 2021
(This article belongs to the Section Oral Medicine and Dentistry)
Browse Figures
Review Reports Versions Notes

Abstract

:
Background: Very few studies of the antiviral potential of lignosulfonates have been published. With the aim of oral application, among various groups of natural products, the relative antiviral potency of lignosulfonate and its ability to rapidly inactivate viruses were investigated. Methods: As target cells, MT-4 cells in suspension and attached Vero cells were used for infections with human immunodeficiency virus (HIV) and human herpes simplex type-1 virus (HSV). Mock- or virus-infected cells were incubated for 3–5 days with various concentrations of test samples, and the viable cell number was determined with the MTT method. For the shorter exposure experiments, higher titers of HIV or HSV were exposed to test samples for 10 or 3 min, diluted to a normal multiplicity of infection (MOI), and applied to the cells. Antiviral activity was quantified by using the chemotherapy index. Results: In the long-exposure system, lignosulfonates showed comparable anti-HIV activity with those of AZT, ddC, and sulfated polysaccharides, and it exceeded those of hundreds of tannins and flavonoids. When the exposure time was shortened, the chemotherapeutic index of the lignosulfonates for HIV was increased 27-fold. At a physiological pH, lignosulfonate showed higher anti-HIV activity than commercial alkali-lignin, dealkali-lignin, and humic acid, possibly due to the higher solubility and purity. Conclusions: With their rapid virus-inactivation capabilities, lignosulfonates may be useful for the prevention or treatment of virally induced oral diseases.

1. Introduction

Due to the worldwide spread of COVID-19, the antiviral potential of natural products has been re-evaluated [1,2]. This has been reflected by the increase in the number of papers on the antiviral activity of natural products (plant extracts, polysaccharides, flavonoids, tannins, and lignins) over the 30 years from 1991 to 2020 (Figure 1). The number of publications on Traditional Chinese Medicine (TCM) rapidly increased in 2020 and surpassed those on plant extracts, which were followed by flavonoids, while publications on sulfated polysaccharide and lignin stayed unchanged or increased very slowly (Figure 1).
Publications on subgroups (Groups 1–5, Table 1) were surveyed. The number of published papers on anti-HIV (human immunodeficiency virus) and anti-HSV (herpes simplex virus type-1) activity was approximately 10% of the number of publications on all viruses. With respect to plant extracts (Group 1), there were more than 25 times more publications on Traditional Chinese Medicine (TCM) than on Traditional Japanese Medicine (Kampo Medicine), hot-water extracts, and alkaline extracts. For flavonoids (Group 2), antiviral studies on flavonol, isoflavone, and commercially available resveratrol and curcumin were the most abundant. Among tannin-related compounds, gallic acid (a component unit of tannin), epigallocatechin gallate, and catechin were the most popular. However, the antiviral activity of most of these lower-molecular-weight compounds was low [3]. For polysaccharides (Group 2), the number of publications on sulfated polysaccharides represented approximately 10% of the publications on all polysaccharides. On the other hand, the numbers of papers on the antiviral activity of natural and synthetic lignin and lignosulfonate were much lower. When a search was conducted for the antiviral activity of lignosulfonate, only six papers were found: four papers dealt with anti-HIV and/or anti-HSV activity [4,5,6,7], one paper with anti-diabetic activity [8], and one paper with anti-inflammatory activity [9]. The anti-HIV mechanism of lignosulfonate is the inhibition of viral penetration via the interaction with viral envelop glycoprotein [5,6], which is similar to the mechanism of sulfated polysaccharide [10,11]. However, the potency of lignosulfonate relative to that of other natural products has not yet been reported.
Lignins, the major class of natural products present in the natural kingdom, are formed by the dehydrogenative polymerization of three monolignols: p-coumaryl, p-coniferyl, and sinapyl alcohols [12]. Some polysaccharides in the cell walls of lignified plants are linked to lignin, forming lignin-carbohydrate complexes (LCCs). The carbohydrate portion of LCC is composed of heterologous sugars such as glucose, arabinose, mannose, galactose, fucose, and occasionally uronic acids, depending on the plant species. When the ratio of polysaccharides to phenylpropanoids varies, the heterogeneity in the acidity, water solubility, ethanol insolubility, and molecular weight are generated. The molecular weight of LCCs ranges from 2.0 to 35 kDa [13,14,15]. Due to the large molecular mass, the biological availability of lignin was disappointingly low. Only a small % of orally administered 125I-lignin was recovered from the blood, while most of the input radioactivity was excreted into feces [16]. On the other hand, lignin showed a strong affinity to the influenza virus (demonstrated by sucrose gradient centrifugation) and instantly eliminated the lethality of influenza virus infection against monkeys [17]. These data suggest that the antiviral activity of lignosulfonate may be maximized by its direct application to the affected part of the body, such as the oral cavity, where numerous bacteria and viruses are present.
The importance of oral health has been reported by many papers. A population-based longitudinal study demonstrated the association of tooth loss rate with the risk of mild cognitive impairment in older adults [18]. Oral function is essential for nutrient intake and can be restored by dental prosthetic treatments in patients with tooth loss [19]. Supportive periodontal treatment with repeated oral hygiene education increased the cumulative survival rates [20]. Many viruses such as human immunodeficiency virus (HIV), herpes simplex virus (HSV) 1 and 2, human cytomegalovirus, Epstein-Barr virus, BK virus, JC virus, and adeno-associated virus (AAV) stimulate the development of genital- and oral-HPV-associated carcinomas [21], and possibly periodontal inflammation [22]. Epigallocatechin-3-gallate (EGCG) gel [23,24] has been applied as a dental anti-caries, although the anti-HIV activity of condensed tannins, including EGCG, was very low [25].
We have previously reported that (i) the alkaline extracts of several tea leaves [26] and licorice root [27] shows higher anti-HIV activity than the corresponding hot water extracts; (ii) hot water extracts such as 10 Kampo medicines and their 25 constituent plant extracts [28], and three Chinese herbal extracts (TCM) from Drynaria baronii, Angelica sinensis, and Cornus officinalis. Sieb. et Zucc [29] showed little or no anti-HIV activity; (iii) purification of lignin from the alkaline extract of the leaves of Sasa sp. by repeated acid-precipitation and solubilization steps resulted in the increase in anti-HIV activity [30]; (iv) lignin sulfonate showed much higher water solubility than lyophilized lignin powder (as shown by this study). In the present pilot experiments, the anti-HIV activity of six newly manufactured lignosulfonates was first investigated in comparison with those of other groups of natural products [3] and commercially available positive controls such as reverse transcriptase inhibitors [azidothymidine (AZT), 2′,3′-dideoxycytidine (ddC)], and sulfated polysaccharides (dextran sulfate, curdlan sulfate). Since alkaline extract of Sasa sp. (SE) that contains LCC [31] has been reported to rapidly inactivate both HIV and HSV [32], whether lignosulfonates rapidly inactivate both HIV and HSV was next investigated for future application to dentistry. Our goal is to manufacture the lignosulfonate-containing gargle or mouth wash that should instantly inactivate HSV and HIV.

2. Materials and Methods

2.1. Materials

The following chemicals and reagents were obtained from the indicated companies: Eagle’s minimum essential medium (MEM) (Gibco BRL, Grand Island, NY, USA); fetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), resveratrol, azidothymidine (AZT), 2′,3′-dideoxycytidine (ddC) (Sigma-Aldrich Inc., St. Louis, MO, USA); dimethyl sulfoxide, dextran sulfate (DS) (5 kDa) (Wako Pure Chemical Ind., Ltd., Osaka, Japan); curdlan sulfate (79 kDa) (Ajinomoto Co., Inc., Tokyo, Japan); and PVP-I (Showa Seiyaku Co. Ltd., Tokyo, Japan); alkali-lignin, dealkali-lignin, humic acid, sodium lignin sulfonate (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan). Culture plastic dishes and plates (96-well) were purchased from Becton Dickinson Labware (Franklin Lakes, NJ, USA).

2.2. Preparation of Lignosulfonate

All lignosulfonates samples used in this study were provided by Nippon Paper Industries Co., Ltd., Tokyo, Japan. Their preparative method, molecular weight (determined by gel permeation chromatography), and purity are shown in Figure 2. Lignosulfonate A is derived from sulfite spent liquor and contains sodium lignosulfonate as the main component. Lignosulfonate B and Lignosulfonate C are purified high-molecular-weight sodium lignosulfonates, and the latter was subjected to additional modifications, including oxidation. Lignosulfonate D is a purified and partly desulfonated sodium lignosulfonate produced under alkaline conditions at a high temperature and pressure. Lignosulfonate E is a type similar to Lignosulfonate D but has higher purity due to the inclusion of a washing procedure. Lignosulfonate F is also a similar type as Lignosulfonate D. Lignosulfonate F is weakly acidic, while Lignosulfonate D is weakly alkaline, and the water solubility of Lignosulfonate F is lower than that of Lignosulfonate D. Lignin, including lignosulfonate, and does not have uniform structures since lignin is formed by polymerization of primary lignin precursors in a relatively random way called ‘Dehydrogenative polymerization.’ Thus, only tentative structures of lignosulfonates have been proposed [33].

2.3. Assay for Antiviral Activity

2.3.1. Assay for Anti-HIV Activity (Using Both Long- and Short-Exposure Systems)

Sample was dissolved at 10 mg/mL with phosphate-buffered saline (PBS, pH 7.4) or 1.39% NaHCO3, vortexed, and shaken overnight at 4 °C. After centrifugation, the supernatant was collected and sterilized by passing through the 0.45 µm membrane filter. For the long-exposure protocol, MT-4 cells (3 × 104 cells) were incubated with HIV at multiplicity of infection (MOI) of 0.01. HIV-and mock-infected MT-4 cells were cultured for 5 days with serial dilutions of lignosulfonates, and the cell viability was quantified with the MTT method [34] (Figure 3A). For the short-exposure protocol, the 20-fold concentrated HIV (MOI = 0.2) was incubated with lignosulfonates at different concentrations for 10 min, then the mixtures were diluted 20-fold and then added to MT-4 cells, and cultured for 5 days at the MOI of 0.01. For the evaluation of cytotoxicity, MT-4 cells were incubated with lignosulfonates at the indicated concentrations for 10 min. After removal of lignosulfonates by centrifugation, MT-4 cells were rinsed with PBS, and then cultured for 5 days to determine the viable cell number with the MTT method (Figure 3B).
From the dose-response curve, the 50% cytotoxic concentration (CC50) in mock-infected cells and the 50% effective concentration (EC50) in HIV-infected cells were determined. The EC50 value was defined as the concentration at which the viability was restored to 50% that of the mock-infected cells. The anti-HIV activity was evaluated by the selectivity index (SI), which was calculated using the following equation: SI = CC50/EC50 (Figure 3C).

2.3.2. Assay for Anti-HSV Activity (Using Only the Short-Exposure System)

Sample was dissolved at 10 mg/mL with phosphate-buffered saline (PBS, pH 7.4) or 1.39% NaHCO3, vortexed, and shaken overnight at 4 °C. After centrifugation, the supernatant was collected and then sterilized by passing through 0.45 µm membrane filter. Mock-infected Vero cells, derived from African green monkey kidney cells, were first treated for short period (3 min) with various concentrations of test samples without HSV, then the supernatant that contained sample was removed by suction. The cells were washed once with PBS and incubated for 3 days in the fresh culture medium. The viability of mock-infected cells was determined by the MTT method. The CC50 was determined from the dose-response curve [32].
For the virus infection, 100-fold concentrated HSV (MOI = 1) was mixed with the test samples and stood for 3 min to expose the cells to extremely higher concentrations of samples. Then, virus titer was reduced 100-fold up to the MOI of 0.01, added to the cells, and incubated for three days to determine the EC50 (Figure 4A). The HSV infection at MOI of 0.01 reduced the cell viability to 20~40% (Supplementary Figure S1). If higher titer of MOI was used, the complete recovery of the cell viability by any sample could not be guaranteed. Three days’ incubation was the optimal condition for the quantitative determination of anti-HSV activity.
From the dose-response curve, the CC50 value in mock-infected cells and the EC50 value in HSV-infected cells were determined. EC50-I was defined as the concentration that restored the viability to the midpoint between that of HSV-infected cells and that of mock-infected cells. EC50-II was defined as the concentration that restored the viability to 50% that of mock-infected cells. Anti-HSV activity was evaluated by the selectivity index (SI-I and SI-II), determined using the following equation: SI-I = CC50/EC50-I; SI-II = CC50/EC50-II (Figure 4B) [32].

2.4. Statistical Treatment

Experiment values are expressed as the mean ± S.D. of triplicate unless otherwise stated.

3. Results

3.1. Lignosulfonate Rapidly Inactivates HIV

3.1.1. Lignosulfonate Is the First Class of Anti-HIV Agent (Long-Exposure Experiment)

MT-4, HTLV-I-transformed T-cell line was used to measure the anti-HIV activity of samples. HIV infection (M.O.I = 0.01) induced the complete loss of viability, accompanied by syncytia formation and the inhibition of HIV-specific antigen expression [7]. The addition of lignosulfonate B rescued the cells from the cytopathic effect of HIV infection. Lignosulfonate B showed potent anti-HIV activity (SI > 1210), comparable with those of sulfated polysaccharides (dextran sulfate, curdlan sulfate) and reverse transferase inhibitors (azidothymidine (AZT) and 2′,3′-dideoxycytidine (ddC)) (Figure 5). Repeated experiments revealed that lignosulfonate B, dextran sulfate, and curdlan sulfate exclusively eliminated the HIV-induced cytopathic effect, whereas the protective effects of AZT and ddC were not complete (Figure 5 and Supplementary Figure S2 Exp. I and II).
Next, the anti-HIV activity of these samples was compared with those of other natural products (Figure 6). Lignosulfonate B (B), sulfated polysaccharides (sodium paramylon sulfate [35], dextran sulfate, and curdlan sulfate) (E), reverse transcriptase inhibitors (AZT, ddC) (A), indicated by orange color, showed the highest anti-HIV activity. This was followed by natural and synthetic lignin (dehydrogenation polymers of phenylpropanoids) (C, D) [36], and alkaline plant extract (G), indicated by green color.
On the other hand, the anti-HIV activity of polysaccharides (unsubstituted or substituted with N,N-dimethylaminoethyl, N,N-diethylaminoethyl, 2-hydroxy-3-trimethylammoniopropyl, and carboxymethyl group) (F) [35], hot water plant extract (Kampo medicines and its constituent plant extracts) (H) [28], tannins (I) [25], and flavonoids and chromones (J) (indicated by blue bars) [3,37,38,39] were much less. It should be noted that the anti-HIV activity of hydrolyzable tannins increased with oligomerization (monomer < dimer < trimer < tetramer) [25].

3.1.2. Enhancement of Anti-HIV Potential of Lignosulfonate by Shortening Treatment Time

We next investigated the possibility of rapid inactivation of HIV-1 by the short exposure to lignosulfonates (A, B, C, D, E, and F). The 20-fold concentrated HIV (MOI = 0.2) was first exposed to higher concentrations of samples for 10 min, diluted, and then added to MT-4 cells. The viable cell number was determined after 5 days with the MTT method. Aliquots of cells were treated with higher concentrations of test samples, washed with PBS, and incubated for 5 days to determine the CC50 value. The SI value was determined by the following equation: SI = CC50/EC50 (Figure 7). Lignosulfonate B showed the highest SI value (SI = 32854), followed by lignosulfonate C (SI > 17982) > lignosulfonate E (SI > 16529) > lignosulfonate D (SI > 15652) > lignosulfonate F (SI > 9733) > lignosulfonate A (SI > 261). Slight but apparent anti-HIV activity of lignosulfonates B, C, E, and F was detected at the concentration of as little as 5.12 ng/mL.
By shortening the exposure time, anti-HIV activity of lignosulfonate B was increased by 27.2-fold, based on the specific index (from SI = 1210 to SI = 32854), or 25.7-fold, based on the EC50 value (=0.826/0.0322), (Table 2). This indicates that more pronounced anti-HIV potential of lignosulfonate would be expected when it is used as quick inactivator of a virus. On the other hand, the increase in anti-HIV-activity of dextran sulfate, curdlan sulfate, AZT and ddC by shortening the exposure time was only 0.7-fold {= [(0.0395 + 0.0593 + 0.0419)/3]/0.0645}, 2.6-fold {= [(0.668 + 0.208 + 0.133)/3]/0.13}, 0.9-fold {= [(0.0168 + 0.0165 + 0.0098)/3]/0.0168}, and 2.8-fold {= [(3.07 + 3.62 + 3.88)/3]/1.25}, respectively (Table 2 and Supplementary Data Figure S2 Exp. 1 and Exp. 2).
We found that lignosulfonates B and C with higher molecular weights showed higher anti-HIV activity than other lignosulfonates. Lignosulfonate A, which contains 50% impurities (Figure 2), showed the lowest anti-HIV activity (SI > 261) (Table 2).
Since the anti-HIV activity (assessed as SI value (=CC50/EC50) of four positive controls (dextran sulfate, curdlan sulfate, AZT, ddC) changed considerably from experiment to experiment (Supplementary Table S1), the anti-HIV activity of lignosulfonate samples and these positive controls were assayed at the same time. The dose-response curve demonstrated that most of the CC50 values of lignosulfonates scaled over the maximum value due to low cytotoxicity, making the EC50 value dominant for SI determination. Variation of standard deviation (SD) of the EC50 value in each point was at most 5~10%, in contrast to the great difference of SI values between samples. For example, the SI value of lignosulfonate A was approximately100-fold lower than other lignosulfonates B, C, D, E and F (that showed comparable or much higher SI values than positive controls). This indicates the obtained SI values are reliable.

3.2. Lignosulfonate Rapidly Inactivates HSV (Short Exposure)

The possibility of rapid inactivation of HSV-1 by short exposure to lignosulfonates A, B, C, D, E, and F was next investigated. One hundred-fold concentrated HSV was exposed for 3 min to various concentrations of test samples. The virus-containing medium was diluted 100-fold and added to the Vero cells. After incubation for 3 days, the EC50 value was determined. Since HSV infection could not completely eradicate the viable cells (leaving 23.4–48.2% of viable cells), two sets of EC50 values, that is, EC50-I and EC50-II, were calculated as described in Materials and Methods. The CC50 value was determined by incubating Vero cells with different concentrations of test samples, washing with PBS, and further incubating for 3 days (Figure 5). Accordingly, two SI values were produced: SI-I (=CC50/EC50-I) and SI-II (=CC50/EC50-II). As a control, commercially available alkali-lignin, dealkali-lignin, and humic acid (chromogenic and structurally irregular organic assemblies that are widespread in soils, rivers, oceans, and coal-related natural resources) [40] were used.
Among six lignosulfonates, lignosulfonate B showed the highest anti-HSV activity based on the SI value. On the other hand, lignosulfonate A and F showed the lowest SI value, regardless of dissolving them with an alkaline solution (1.39%NaHCO3, pH 8.0) or with a neutral buffer (phosphate-buffered saline, pH 7.4) (Figure 8, Table 3). Highly purified lignosulfonate E (purity: 97%) showed higher anti-HSV activity when it was dissolved in PBS (−).
Alkali-lignin, dealkali-lignin, and humic acid showed anti-HSV activity comparable with that of lignosulfonate B; when they were dissolved with an alkaline solution, however, their anti-HIV activity was dramatically reduced by dissolving them with neutral buffer (Figure 9, Table 3). This indicates that solubility is an essential factor that determines the anti-HSV activity.

4. Discussion

The present study further confirmed the excellent antiviral activity of lignosulfonate [4,5,6,7], and its antiviral activity was comparable with those of sulfated polysaccharides and much higher than those of other lower polyphenols (Figure 6). During the isolation process, lignin forms the complex with polysaccharides. Anti-influenza A virus and HIV activities of lignin-carbohydrate complex (LCC) were considerably reduced by treatment with sodium chlorite but were not affected by sulfuric acid or trifluoroacetic acid [7,41,42], confirming that the active principle of LCC is the polymerized phenolic structure [29], but not carbohydrate. This was supported by the excellent antiviral activity of synthetic lignin (dehydrogenation polymer of phenylpropanoids) without polysaccharides [36]. Both lignin and polysaccharide provide scaffolds for the attachment of a sulfonate or sulfate group. The antiviral activity of lignosulfonate may depend on the molecular size since lignosulfonates B and C, which have higher molecular weight than other lignosulfonates, showed higher anti-HIV activity (Table 2). The substitution ratio of the sulfate group may also affect the antiviral activity of sulfated polysaccharides [35].
The anti-HSV activity of commercially available lignosulfonate, alkali-lignin, dealkali-lignin, and humic acid depends on their solubility. When these substances were dissolved with 1.39% NaHCO3 (pH 8.0), they showed anti-HSV activity comparable with each other (Figure 8). However, when they were dissolved with a neutral buffer, PBS (pH 7.4), their anti-HSV activity diminished (Figure 9), in contrast to lignosulfonates, which dissolved well in both alkaline and neutral solutions (Figure 8).
The purity of the sample is another factor that determines the antiviral activity. Lignosulfonate A (purity: 50%) showed much lower anti-HIV activity (SI > 261) than lignosulfonate B-F (purity: 92, 81, 87, 97 and 89, respectively) (SI >9733–32854) (Figure 7). Commercial lignosulfonate showed slightly lower anti-HSV activity (SI >3.7, >4.5) when dissolved in PBS (as shown in Supplementary Figure S3), as compared with those of lignosulfonate B (SI = 14.1, >21.7) and lignosulfonate E (SI = >16.1, >21.7).
The anti-HIV activity of lignosulfonate B was enhanced 27.2-fold when the treatment period was shortened (Table 2). On the other hand, the reduction in the exposure time did not enhance the anti-HIV activity of sulfated polysaccharides (dextran sulfate, curdlan sulfate) and reverse transcriptase inhibitors (AZT, ddC). This may be explained by the fact that lignosulfonate B, with both a polymerized phenolic structure and sulfonate groups, may adsorb the virus more quickly than sulfated polysaccharides and reverse transcriptase inhibitors. Although the anti-HIV activity of resveratrol and curcumin is two or three orders lower than lignosulfonate (Figure 6), their antiviral activity may be enhanced by adopting a short treatment schedule.
Alkaline extract of Sasa sp. (SE) showed comparable anti-HIV activity with that of natural and synthetic lignin [36], leading to the manufacture of toothpaste that includes 29% SE [43]. The present study demonstrated that lignosulfonate B showed 28–42-fold higher anti-HIV activity (EC50 = 0.0322 μg/mL) (Table 2) than SE (EC50 = 0.89–1.35 μg/mL) [32], and rapidly inactivated HIV and HSV. Considering that the chemotherapy index of SE is one order higher than that of povidone iodine (the most popular gargling solution in Japan) (SI = 26.1–31.6 vs. 2–3.1) [32], the chemotherapy index of lignosulfonate is estimated to be two or three orders higher than that of povidone iodine. The rapid virus inactivation activity of lignosulfonate suggests its applicability as a toothpaste and mouth washer to prevent viral infection.
Lignosulfonate B, but not AZT and ddC, completely inhibited the cytopathic effect of HIV infection (Figure 7). Considering the synergism of SE and antiviral agents [44], the combined treatment of lignosulfonate and AZT or ddC, having different cellular targets on HIV-induced cytopathy, may be efficacious.
Oral health is important for living a longer life since the oral cavity contains a lot of microorganisms such as bacteria and viruses. Most researchers have focused on bacteria affecting quality of life. However, not only bacteria but also viruses may have ill effects on oral function. Oral herpes virus is very common and often causes debilitating infectious diseases in patients, affecting oral health and having serious psychological implications [45]. HIV is a blood-borne virus that can enter the mouth via gingival crevicular fluid and hides in the oral HIV reservoir [46]. Due to the behavioral changes in sexual conduct, conventional oral transmission of sexually transmitted HIV infections has been progressively recognized. Pediatric infections could also be the result of breastfeeding by the oral route. Pathogenic viruses such as HIV and HSV come with an array of complexities in the oral cavity, and therefore, keeping a clean mouth is essential for living longer with a high QOL. Oral intake of SE significantly improved the symptoms of oral lichenoid dysplasia (as evidenced by the reduced area of white steaks and the decline of the salivary concentrations of interleukin-6 and -8) [47], possibly by its potent anti-inflammatory activity [48].
SARS-CoV-2 exhibits several complications, such as lung damage, blood clot formation, respiratory illness, organ failures [49], and neurologic manifestations such as taste [50] and smell loss [51] in most patients. At present, there is no report available for anticoronavirus activity of both lignosulfonate and sulfated polysaccharides. Since these substances prevent virus entry into host cells, they can be used as candidate drugs, adjuvants in vaccines, or in combination with other antivirals, antioxidants, and immune-activating nutritional supplements and antiviral materials to prevent SARS-CoV-2 infection [49]. The anti-diabetic [8], anti-inflammatory [9], and antiviral activity (this study) of lignosulfonate, and the neuroprotective activity of lignin [52] and SE [53] may be advantageous for the treatment of COVID-19.
Lignin that contains mannose in the polysaccharide portion has been reported to stimulate the expression of the mRNA of dectin-2 [54], a C-type lectin receptor that recognizes high-mannose polysaccharides [55]. Research into the distribution of dectin-2 in oral tissues and its role in immunopotentiation is underway.

5. Conclusions

Lignin is a main constituent of wood, such as cellulose and hemicellulose, and is found abundantly in nature. The present study demonstrates for the first time that lignosulfonate is a first-class anti-HIV agent, and it rapidly inactivates HIV and HSV. These data suggest its possible utilization as an ingredient in gargle mouthwash and toothpaste.

Supplementary Materials

The following is available online at https://www.mdpi.com/article/10.3390/medicines8100056/s1, Figure S1: Determination of optimal dilution fold to achieve quantifiable anti-HSV activity; Figure S2: Sulfated glucan achieved higher recovery than reverse transcriptase inhibitors; Figure S3: Commercial lignosulfonate showed slightly lower anti-HSV activity when dissolved in PBS, as compared with lignosulfonate B and lignosulfonate E. Table S1. Variability of anti-HIV activity (SI value) of four positive controls reported in our 26 papers.

Author Contributions

Conceptualization, H.S.; methodology, K.F., T.K. (Takuro Koshikawa) and D.A.; resources, H.A. and Y.K.; data curation, H.S.; writing—original draft preparation, H.S.; writing—review and editing, D.A., M.I., H.T. and T.K. (Taisei Kanamoto); supervision, H.S., H.A. and Y.K.; funding acquisition, H.S. and K.F. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded in part by KAKENHI from the Japan Society for the Promotion of Science (JSPS) (No. 20K09885) for the assay of the antiviral effect of chromone derivatives (H.S); the Showa University Graduate School Research Fund of 2020 (Analysis of protection of herpes simplex virus infection by natural substances) (K.F.); the St. Marianna University School of Medicine Research Fund allotted to each department (T.K. (Takuro Koshikawa) and D.A.), and the Meikai University Miyata Research Fund B (H.S.).

Institutional Review Board Statement

Ethical review and approval were waived for this study since we only used cell lines purchased from the Riken Cell Bank.

Informed Consent Statement

Not applicable since we did not use a clinical sample.

Acknowledgments

We acknowledge Shigemi Terakubo for technical support for the anti-HIV assay.

Conflicts of Interest

H.A. and Y.K. come from Nippon Paper Industries Co., Ltd., Japan. The corresponding author (H.S.) received the supply of purified samples of lignosulfonates from Nippon Paper Industries Co., Ltd. The authors confirm that such supports have not influenced the outcome of the experimental data. The other authors declare no conflict of interest.

References

  1. Khadka, D.; Dhamala, M.K.; Li, F.; Aryal, P.C.; Magar, P.R.; Bhatta, S.; Thakur, M.S.; Basnet, A.; Cui, D.; Shi, S. The use of medicinal plants to prevent COVID-19 in Nepal. J. Ethnobiol. Ethnomed. 2021, 17, 26. [Google Scholar] [CrossRef] [PubMed]
  2. Nguyen, T.T.H.; Jung, J.H.; Kim, M.K.; Lim, S.; Choi, J.M.; Chung, B.; Kim, D.W.; Kim, D. The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship. Molecules 2021, 26, 1924. [Google Scholar] [CrossRef] [PubMed]
  3. Sakagami, H. Biological activities and possible dental application of three major groups of polyphenols. J. Pharmacol. Sci. 2014, 126, 92–106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Qiu, M.; Wang, Q.; Chu, Y.; Yuan, Z.; Song, H.; Chen, Z.; Wu, Z. Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission. PLoS ONE 2012, 7, e35906. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Gordts, S.C.; Férir, G.; D’Huys, T.; Petrova, M.I.; Lebeer, S.; Snoeck, R.; Andrei, G.; Schols, D. The Low-Cost Compound Lignosulfonic Acid (LA) Exhibits Broad-Spectrum Anti-HIV and Anti-HSV Activity and Has Potential for Microbicidal Applications. PLoS ONE 2015, 10, e0131219. [Google Scholar] [CrossRef] [PubMed]
  6. Oeyen, M.; Noppen, S.; Vanhulle, E.; Claes, S.; Myrvold, B.O.; Vermeire, K.; Schols, D. A unique class of lignin derivatives displays broad anti-HIV activity by interacting with the viral envelope. Virus Res. 2019, 274, 197760. [Google Scholar] [CrossRef]
  7. Suzuki, H.; Tochikura, T.S.; Iiyama, K.; Yamazaki, S.; Yamamoto, N.; Toda, S. Lignosulfonate, a water-solubilized lignin from the waste liquor of the pulping process, inhibis the infectivity and cytophathic effects of human immunodficiency virus in vitro. Agric. Biol. Chem. 1989, 53, 3369–3372. [Google Scholar]
  8. Hasegawa, Y.; Kadota, Y.; Hasegawa, C.; Kawaminami, S. Lignosulfonic Acid-Induced Inhibition of Intestinal Glucose Absorption. J. Nutr. Sci. Vitaminol. 2015, 61, 449–454. [Google Scholar] [CrossRef] [Green Version]
  9. Matsuhisa, K.; Watari, A.; Iwamoto, K.; Kondoh, M.; Yagi, K. Lignosulfonic acid attenuates NF-κB activation and intestinal epithelial barrier dysfunction induced by TNF-α/IFN-γ in Caco-2 cells. J. Nat. Med. 2018, 72, 448–455. [Google Scholar] [CrossRef]
  10. Pomin, V.H.; Bezerra, F.F.; Soares, P.A.G. Sulfated Glycans in HIV Infection and Therapy. Curr. Pharm. Des. 2017, 23, 3405–3414. [Google Scholar] [CrossRef]
  11. Cardozo, F.T.; Camelini, C.M.; Leal, P.C.; Kratz, J.M.; Nunes, R.J.; Mendonça, M.M.; Simões, C.M. Antiherpetic mechanism of a sulfated derivative of Agaricus brasiliensis fruiting bodies polysaccharide. Intervirology 2014, 57, 375–383. [Google Scholar] [CrossRef]
  12. Lewis, N.G.; Yamamoto, E. Lignin: Occurrence, biogenesis and biodegradation. Annu. Rev. Plant Biol. 1990, 41, 455–496. [Google Scholar] [CrossRef] [PubMed]
  13. Kimura, C.; Li, R.; Ouda, R.; Nishimura, H.; Fujita, T.; Watanabe, T. Production of Antiviral Substance from Sugarcane Bagasse by Chemical Alteration of its Native Lignin Structure through Microwave Solvolysis. ChemSusChem 2020, 13, 4519–4527. [Google Scholar] [CrossRef]
  14. Mirpoor, S.F.; Restaino, O.F.; Schiraldi, C.; Giosafatto, C.V.L.; Ruffo, F.; Porta, R. Lignin/Carbohydrate Complex Isolated from Posidonia oceanica Sea Balls (Egagropili): Characterization and Antioxidant Reinforcement of Protein-Based Films. Int. J. Mol. Sci. 2021, 22, 9147. [Google Scholar] [CrossRef] [PubMed]
  15. Zhang, Y.; But, P.P.; Ooi, V.E.; Xu, H.X.; Delaney, G.D.; Lee, S.H.; Lee, S.F. Chemical properties, mode of action, and in vivo anti-herpes activities of a lignin-carbohydrate complex from Prunella vulgaris. Antivir. Res. 2007, 75, 242–249. [Google Scholar] [CrossRef]
  16. Sakagami, H.; Asano, K.; Yoshida, T.; Kawazoe, Y. Organ distribution and toxicity of lignin. In Vivo 1999, 13, 41–44. [Google Scholar] [PubMed]
  17. Sakagami, H.; Takeda, M.; Kawazoe, Y.; Nagata, K.; Ishihama, A.; Ueda, M.; Yamazaki, S. Anti-influenza virus activity of a lignin fraction from cone of Pinus parviflora Sieb. et Zucc. In Vivo 1992, 6, 491–495. [Google Scholar]
  18. Xu, S.; Huang, X.; Gong, Y.; Sun, J. Association between tooth loss rate and risk of mild cognitive impairment in older adults: A population-based longitudinal study. Aging 2021, 13. [Google Scholar] [CrossRef]
  19. Kusama, T.; Nakazawa, N.; Kiuchi, S.; Kondo, K.; Osaka, K.; Aida, J. Dental prosthetic treatment reduced the risk of weight loss among older adults with tooth loss. J. Am. Geriatr. Soc. 2021, 69, 2498–2506. [Google Scholar] [CrossRef]
  20. Han, J.Y.; Park, S.H.; Kim, J.; Hwang, K.G.; Park, C.J. Clinical factors affecting the longevity of fixed retainers and the influence of fixed retainers on periodontal health in periodontitis patients: A retrospective study. J. Periodontal Implant. Sci. 2021, 51, 163–178. [Google Scholar] [CrossRef]
  21. Guidry, J.T.; Scott, R.S. The interaction between human papillomavirus and other viruses. Virus Res. 2017, 231, 139–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Shigeishi, H.; Su, C.Y.; Kaneyasu, Y.; Matsumura, M.; Nakamura, M.; Ishikawa, M.; Saito, A.; Ohta, K.; Sugiyama, M. Association of oral HPV16 infection with periodontal inflammation and the oral microbiome in older women. Exp. Ther. Med. 2021, 21, 167. [Google Scholar] [CrossRef] [PubMed]
  23. Xu, X.; Dai, Z.; Zhang, Z.; Kou, X.; You, X.; Sun, H.; Guo, H.; Liu, M.; Zhu, H. Fabrication of oral nanovesicle in-situ gel based on Epigallocatechin gallate phospholipid complex: Application in dental anti-caries. Eur. J. Pharmacol. 2021, 897, 173951. [Google Scholar] [CrossRef] [PubMed]
  24. Landmayer, K.; Liberatti, G.A.; Farias-Neto, A.M.; Wang, L.; Honório, H.M.; Francisconi-Dos-Rios, L.F. Could applying gels containing chlorhexidine, epigallocatechin-3-gallate, or proanthocyanidin to control tooth wear progression improve bond strength to eroded dentin? J. Prosthet. Dent. 2020, 124, 798.e791–798.e797. [Google Scholar] [CrossRef]
  25. Nakashima, H.; Murakami, T.; Yamamoto, N.; Sakagami, H.; Tanuma, S.; Hatano, T.; Yoshida, T.; Okuda, T. Inhibition of human immunodeficiency viral replication by tannins and related compounds. Antivir. Res. 1992, 18, 91–103. [Google Scholar] [CrossRef]
  26. Sakagami, H.; Ohkoshi, E.; Amano, S.; Satoh, K.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Sunaga, K.; Otsuki, T.; Ikeda, H.; et al. Efficient utilization of plant resources by alkaline extraction. Altern. Integr. Med. 2013, 2, 133. [Google Scholar] [CrossRef]
  27. Ohno, H.; Miyoshi, S.; Araho, D.; Kanamoato, T.; Terakubo, S.; Nakashima, H.; Tsuda, T.; Sunaga, K.; Amano, S.; Ohkoshi, E.; et al. Efficient utilization of licorice root by alkaline extraction. In Vivo 2014, 28, 785–794. [Google Scholar]
  28. Kato, T.; Horie, N.; Matsuta, T.; Naoki, U.; Shimoyama, T.; Kaneko, T.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Kusama, K.; et al. Anti-UV/HIV activity of Kampo medicines and constituent plant extracts. In Vivo 2012, 26, 1007–1013. [Google Scholar]
  29. Chu, Q.; Satoh, K.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Wang, Q.; Sakagami, H. Antitumor potential of three herbal extracts against human oral squamous cell lines. Anticancer Res. 2009, 29, 3211–3219. [Google Scholar]
  30. Sakagami, H.; Zhou, L.; Kawano, M.; Thet, M.M.; Tanaka, S.; Machino, M.; Amano, S.; Kuroshita, R.; Watanabe, S.; Chu, Q.; et al. Multiple biological complex of alkaline extract of the leaves of Sasa senanensis Rehder. In Vivo 2010, 24, 735–743. [Google Scholar]
  31. Sakagami, H.; Kushida, T.; Oizumi, T.; Nakashima, H.; Makino, T. Distribution of lignin-carbohydrate complex in plant kingdom and its functionality as alternative medicine. Pharmacol. Ther. 2010, 128, 91–105. [Google Scholar] [CrossRef]
  32. Fukuchi, K.; Sakagami, H.; Sugita, Y.; Takao, K.; Asai, D.; Terakubo, S.; Takemura, H.; Ohno, H.; Horiuchi, M.; Suguro, M.; et al. Quantification of the Ability of Natural Products to Prevent Herpes Virus Infection. Medicines 2020, 7, 64. [Google Scholar] [CrossRef]
  33. Glennie, D.W. Reactions in sulfite pulping. In Lignins, Occurrence, Formation, Structure and Reactions; Sarkanen, K.V., Ludwig, C.H., Eds.; Wiley-Interscience: New York, NY, USA; Sydney, Australia; Toronto, ON, Canada, 1971; p. 607. [Google Scholar]
  34. Nakashima, H.; Masuda, M.; Murakami, T.; Koyanagi, Y.; Matsumoto, A.; Fujii, N.; Yamamoto, N. Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7] polyphemusin II): A possible inhibitor of virus-cell fusion. Antimicrob. Agents Chemother. 1992, 36, 1249–1255. [Google Scholar] [CrossRef] [Green Version]
  35. Koizumi, N.; Sakagami, H.; Utsumi, A.; Fujinaga, S.; Takeda, M.; Asano, K.; Sugawara, I.; Ichikawa, S.; Kondo, H.; Mori, S.; et al. Anti-HIV (human immunodeficiency virus) activity of sulfated paramylon. Antivir. Res. 1993, 21, 1–14. [Google Scholar] [CrossRef]
  36. Nakashima, H.; Murakami, T.; Yamamoto, N.; Naoe, T.; Kawazoe, Y.; Konno, K.; Sakagami, H. Lignified materials as medicinal resources. V. Anti-HIV (human immunodeficiency virus) activity of some synthetic lignins. Chem. Pharm. Bull. 1992, 40, 2102–2105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Shimada, C.; Uesawa, Y.; Ishii-Nozawa, R.; Ishihara, M.; Kagaya, H.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Takao, K.; Sugita, Y.; et al. Quantitative structure-cytotoxicity relationship of 3-styrylchromones. Anticancer Res. 2014, 34, 5405–5411. [Google Scholar] [PubMed]
  38. Uesawa, Y.; Sakagami, H.; Ishihara, M.; Kagaya, H.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Yahagi, H.; Takao, K.; Sugita, Y. Quantitative Structure-Cytotoxicity Relationship of 3-Styryl-2H-chromenes. Anticancer Res. 2015, 35, 5299–5307. [Google Scholar] [PubMed]
  39. Sakagami, H.; Masuda, Y.; Tomomura, M.; Yokose, S.; Uesawa, Y.; Ikezoe, N.; Asahara, D.; Takao, K.; Kanamoto, T.; Terakubo, S.; et al. Quantitative Structure-Cytotoxicity Relationship of Chalcones. Anticancer Res. 2017, 37, 1091–1098. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Jung, H.; Kwon, S.; Kim, J.H.; Jeon, J.R. Which Traits of Humic Substances Are Investigated to Improve Their Agronomical Value? Molecules 2021, 26, 760. [Google Scholar] [CrossRef]
  41. Harada, H.; Sakagami, H.; Nagata, K.; Oh-hara, T.; Kawazoe, Y.; Ishihama, A.; Hata, N.; Misawa, Y.; Terada, H.; Konno, K. Possible involvement of lignin structure in anti-influenza virus activity. Antivir. Res. 1991, 15, 41–49. [Google Scholar] [CrossRef]
  42. Lai, P.K.; Oh-hara, T.; Tamura, Y.; Kawazoe, Y.; Konno, K.; Sakagami, H.; Tanaka, A.; Nonoyama, M. Polymeric phenylpropenoids are the active components in the pine cone extract that inhibit the replication of type-1 human immunodeficiency virus in vitro. J. Gen. Appl. Microbiol. 1992, 38, 303–323. [Google Scholar] [CrossRef] [Green Version]
  43. Sakagami, H.; Amano, S.; Yasui, T.; Satoh, K.; Shioda, S.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Watanabe, K.; Sugiura, T.; et al. Biological interaction between Sasa senanensis Rehder leaf extract and toothpaste ingredients. In Vivo 2013, 27, 275–284. [Google Scholar]
  44. Sakagami, H.; Fukuchi, K.; Kanamoto, T.; Terakubo, S.; Nakashima, H.; Natori, T.; Suguro-Kitajima, M.; Oizumi, H.; Yasui, T.; Oizumi, T. Synergism of Alkaline Extract of the Leaves of Sasa senanensis Rehder and Antiviral Agents. In Vivo 2016, 30, 421–426. [Google Scholar] [PubMed]
  45. Crimi, S.; Fiorillo, L.; Bianchi, A.; D’Amico, C.; Amoroso, G.; Gorassini, F.; Mastroieni, R.; Marino, S.; Scoglio, C.; Catalano, F.; et al. Herpes Virus, Oral Clinical Signs and QoL: Systematic Review of Recent Data. Viruses 2019, 11, 463. [Google Scholar] [CrossRef] [Green Version]
  46. Shugars, D.C.; Patton, L.L.; Freel, S.A.; Gray, L.R.; Vollmer, R.T.; Eron, J.J., Jr.; Fiscus, S.A. Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva. J. Dent. Res. 2001, 80, 414–420. [Google Scholar] [CrossRef] [PubMed]
  47. Matsuta, T.; Sakagami, H.; Tanaka, S.; Machino, M.; Tomomura, M.; Tomomura, A.; Yasui, T.; Itoh, K.; Sugiura, T.; Kitajima, M.; et al. Pilot clinical study of Sasa senanensis Rehder leaf extract treatment on lichenoid dysplasia. In Vivo 2012, 26, 957–962. [Google Scholar] [PubMed]
  48. Sakagami, H.; Nakatani, S.; Enomoto, A.; Ota, S.; Kaneko, M.; Sugimoto, M.; Horiuchi, M.; Toeda, K.; Oizumi, T. Multi-Omics Analysis of Anti-Inflammatory Action of Alkaline Extract of the Leaves of Sasa sp. J. Clin. Med. 2021, 10, 2100. [Google Scholar] [CrossRef]
  49. Andrew, M.; Jayaraman, G. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19). Carbohydr. Res. 2021, 505, 108326. [Google Scholar] [CrossRef]
  50. Cirillo, N. Taste alteration in COVID-19: Significant geographical differences exist in the prevalence of the symptom. J. Infect. Public Health 2021, 14, 1099–1105. [Google Scholar] [CrossRef]
  51. Doty, R.L. The mechanisms of smell loss after SARS-CoV-2 infection. Lancet Neurol. 2021, 20, 693–695. [Google Scholar] [CrossRef]
  52. Yuan, H.; Yang, Q.; Yang, B.; Xu, H.; Nasif, O.; Muruganantham, S.; Chen, J. Phyllanthin Averts Oxidative Stress and Neuroinflammation in Cerebral Ischemic-Reperfusion Injury through Modulation of the NF-κB and AMPK/Nrf2 Pathways. J. Environ. Pathol. Toxicol. Oncol. 2021, 40, 85–97. [Google Scholar] [CrossRef] [PubMed]
  53. Sakagami, H.; Shi, H.; Bandow, K.; Tomomura, M.; Tomomura, A.; Horiuchi, M.; Fujisawa, T.; Oizumi, T. Search of Neuroprotective Polyphenols Using the “Overlay” Isolation Method. Molecules 2018, 23, 1840. [Google Scholar] [CrossRef] [Green Version]
  54. Kushida, T.; Makino, T.; Tomomura, M.; Tomomura, A.; Sakagami, H. Enhancement of Dectin-2 gene expression by lignin-carbohydrate complex from Lentinus edodes mycelia extract (LEM) in a mouse macrophage-like cell line. Anticancer Res. 2011, 31, 1241–1248. [Google Scholar] [PubMed]
  55. Kitai, Y.; Sato, K.; Tanno, D.; Yuan, X.; Umeki, A.; Kasamatsu, J.; Kanno, E.; Tanno, H.; Hara, H.; Yamasaki, S.; et al. Role of Dectin-2 in the phagocytosis of Cryptococcus neoformans by dendritic cells. Infect. Immun. 2021, 89, e0033021. [Google Scholar] [CrossRef] [PubMed]
Medicines 08 00056 g001 550
Figure 1. Number of publications on antiviral research of natural products over the 30 years from 1991 to 2020. Data were taken from Pubmed (14 April 2021).
Figure 1. Number of publications on antiviral research of natural products over the 30 years from 1991 to 2020. Data were taken from Pubmed (14 April 2021).
Medicines 08 00056 g001
Medicines 08 00056 g002 550
Figure 2. Preparative scheme of lignosulfonate. Purity and molecular weight were characterized by Nippon Paper Industries Co., Ltd., Tokyo, Japan.
Figure 2. Preparative scheme of lignosulfonate. Purity and molecular weight were characterized by Nippon Paper Industries Co., Ltd., Tokyo, Japan.
Medicines 08 00056 g002
Medicines 08 00056 g003 550
Figure 3. Experimental protocol for the determination of anti-HIV activity using long- (A) and short- (B) exposure assay systems, and the dose-response curve for the calculation of CC50, EC50, and SI values (C).
Figure 3. Experimental protocol for the determination of anti-HIV activity using long- (A) and short- (B) exposure assay systems, and the dose-response curve for the calculation of CC50, EC50, and SI values (C).
Medicines 08 00056 g003
Medicines 08 00056 g004 550
Figure 4. Experimental protocol for the determination of anti-HSV activity using the short-exposure assay system (A), and the dose-response curve for the calculation of CC50, EC50, and SI values (B).
Figure 4. Experimental protocol for the determination of anti-HSV activity using the short-exposure assay system (A), and the dose-response curve for the calculation of CC50, EC50, and SI values (B).
Medicines 08 00056 g004
Medicines 08 00056 g005 550
Figure 5. Lignosulfonate B showed comparable anti-HIV activity with sulfated polysaccharides and reverse transcriptase inhibitors. Mock- or HIV (M.O.I = 0.01)-infected MT-4 cells were incubated for 5 days with the indicated concentrations of either lignosulfonate B or four positive controls (dextran sulfate, curdlan sulfate, AZT, ddC), and then the viable cell number was determined by the MTT method, as described in Figure 3A. Each value represents the mean ± S.D. of triplicate assays.
Figure 5. Lignosulfonate B showed comparable anti-HIV activity with sulfated polysaccharides and reverse transcriptase inhibitors. Mock- or HIV (M.O.I = 0.01)-infected MT-4 cells were incubated for 5 days with the indicated concentrations of either lignosulfonate B or four positive controls (dextran sulfate, curdlan sulfate, AZT, ddC), and then the viable cell number was determined by the MTT method, as described in Figure 3A. Each value represents the mean ± S.D. of triplicate assays.
Medicines 08 00056 g005
Medicines 08 00056 g006 550
Figure 6. Lignosulfonate B and sulfated polysaccharides are potent anti-HIV substances. The data of lignosulfonate B (B) and anti-HIV agents (dextran sulfate, curdlan sulfate, AZT, and ddC) (indicated by orange color) were taken from the present study (Figure 2). Data of synthetic lignin were taken from [36], paramylon derivatives from [35], Kampo medicine from [28], hydrolyzable and condensed tannins from [25], chromones and chalcones (J) from [37,38,39], and other data from [3].
Figure 6. Lignosulfonate B and sulfated polysaccharides are potent anti-HIV substances. The data of lignosulfonate B (B) and anti-HIV agents (dextran sulfate, curdlan sulfate, AZT, and ddC) (indicated by orange color) were taken from the present study (Figure 2). Data of synthetic lignin were taken from [36], paramylon derivatives from [35], Kampo medicine from [28], hydrolyzable and condensed tannins from [25], chromones and chalcones (J) from [37,38,39], and other data from [3].
Medicines 08 00056 g006
Medicines 08 00056 g007 550
Figure 7. Anti-HIV activity of 6 lignosulfonates (A) and positive control (B), evaluated by the short-exposure protocol. HIV was incubated with the indicated concentrations of lignosulfonates for 10 min, then the mixtures were added to MT-4 cells and cultured for 5 days. For the evaluation of cytotoxicity, MT-4 cells were incubated with the indicated concentrations of lignosulfonates for 10 min. After removing the lignosulfonates by centrifugation, MT-4 cells were cultured for 5 days. Viable cell number was determined with the MTT method. Each value represents the mean ± S.D. of triplicate assays. It should be noted that HIV infection (M.O.I. = 0.01) induced the complete loss of cell survival, which was returned to control level by the addition of lignosulfonate.
Figure 7. Anti-HIV activity of 6 lignosulfonates (A) and positive control (B), evaluated by the short-exposure protocol. HIV was incubated with the indicated concentrations of lignosulfonates for 10 min, then the mixtures were added to MT-4 cells and cultured for 5 days. For the evaluation of cytotoxicity, MT-4 cells were incubated with the indicated concentrations of lignosulfonates for 10 min. After removing the lignosulfonates by centrifugation, MT-4 cells were cultured for 5 days. Viable cell number was determined with the MTT method. Each value represents the mean ± S.D. of triplicate assays. It should be noted that HIV infection (M.O.I. = 0.01) induced the complete loss of cell survival, which was returned to control level by the addition of lignosulfonate.
Medicines 08 00056 g007
Medicines 08 00056 g008 550
Figure 8. Lignosulfonates showed potent anti-HSV activity regardless of the pH of dissolving solution: 1.39% NaHCO3 (pH 8.0) or phosphate-buffered saline (PBS) (pH 7.4). It should be noted that the viability of HSV-infected cells was reduced to 23.4~48.2%.
Figure 8. Lignosulfonates showed potent anti-HSV activity regardless of the pH of dissolving solution: 1.39% NaHCO3 (pH 8.0) or phosphate-buffered saline (PBS) (pH 7.4). It should be noted that the viability of HSV-infected cells was reduced to 23.4~48.2%.
Medicines 08 00056 g008
Medicines 08 00056 g009 550
Figure 9. Anti-HSV activity of alkali-lignin, dealkali-lignin, and fumic acid declined when they were dissolved with PBS. Each value represents the mean ± S.D. of triplicate assays.
Figure 9. Anti-HSV activity of alkali-lignin, dealkali-lignin, and fumic acid declined when they were dissolved with PBS. Each value represents the mean ± S.D. of triplicate assays.
Medicines 08 00056 g009
Table
Table 1. Number of papers of antiviral research in each classified group (Pubmed search, 14 April 2021).
Table 1. Number of papers of antiviral research in each classified group (Pubmed search, 14 April 2021).
Number of Papers Reported Thus Far
ClassificationSubgroupAntiviralAnti-HIVAnti-HSV
Plant extractsPlant extracts6173564126
(Group 1)Traditional Chinese medicine242911920
Kampo medicine6732
Hot water extract7996
Alkaline extract92164
FlavonoidFlavonoid391123448
(Group 2)Flavonol596195
Flavone400
Flavanone249181
Isoflavone513123
Pterocarpan1230
Coumestan510
Resveratrol328252
Curcumin488310
Tricin1520
TanninsTannin3886016
(Group 3)Hydrolyzable tannin124117
Condensed tannin99102
Procyanidine5182
Gallic acid3222818
Epigallocatechin gallate260211
Catechin487388
PolysaccharidesPolysaccharide1616565651
(Group 4)Sulfated polysaccharide158822931
LigninLignin98325
(Group 5)Synthetic lignin1060
Lignosulfonate531
p-Coumaric acid2881
Table
Table 2. Short exposure of lignosulfonate induced one order higher anti-HIV activity than long exposure.
Table 2. Short exposure of lignosulfonate induced one order higher anti-HIV activity than long exposure.
Test
Compound		Data
Source		CC50 (μg/mL)EC50 (μg/mL)SI
<Short exposure>
Lignosulfonate AFigure 4>4001.53>261
Lignosulfonate B 10560.032232,854
Lignosulfonate C >20000.111>17,982
Lignosulfonate D >20000.128>15,625
Lignosulfonate E >20000.121>16,529
Lignosulfonate F >20000.205>9733
Dextran sulfate >40000.0645>62,016
Curdlan sulfate >40000.130>30,769
AZT (μM) >20000.0168>119,048
ddC (μM) >20,0001.25>16,000
<Long exposure>
Lignosulfonate BFigure 2>10000.826>1210
Dextran sulfate >10000.0395>25,323
Curdlan sulfate 6440.668964
AZT (μM) 42.90.01682550
ddC (μM) 23873.07778
Dextran sulfateSupplementary Figure S21380.05932321
Curdlan sulfate(Exp. 1)9140.2084392
AZT (μM) 1670.016510,090
ddC (μM) 24503.62677
Dextran sulfate(Exp. 2)1550.04193703
Curdlan sulfate 4800.1333614
AZT (μM) 47.40.009804838
ddC (μM) >50003.88>1289
Table
Table 3. Lignosulfonates showed higher anti-HSV activity than other lignified materials when they were dissolved with neutral buffer (PBS). We confirmed that repeated experiments produced similar results.
Table 3. Lignosulfonates showed higher anti-HSV activity than other lignified materials when they were dissolved with neutral buffer (PBS). We confirmed that repeated experiments produced similar results.
Test CompoundSolventViability
of HSV-
Infected Cells (%)		CC50
(mg/mL)		EC50-I
(mg/mL)		EC50-II
(mg/mL)		SI-ISI-IIMax
Recovery
(%)
<Lignosulfonate>
Lignosulfonate ANaHCO323.9>103.51.6>2.9>6.3119
PBS23.4>102.82>3.6>5112
Lignosulfonate BNaHCO343.5>100.520.35>19.2>28.6117
PBS48.2>100.710.46>14.1>21.7120
Lignosulfonate CNaHCO329.9>100.740.55>13.5>18.2110
PBS34.2>101.61.2>6.3>8.3114
Lignosulfonate DNaHCO335.3>101.40.32>7.1>31.391
PBS43>102.61.1>3.8>9.183
Lignosulfonate ENaHCO335.5>101.60.96>6.3>10.4106
PBS23.5>100.620.46>16.1>21.7108
Lignosulfonate FNaHCO324>101.10.45>9.1>22.2117
PBS33>105.54.4>1.8>2.3112
<Other lignified materials>
Alkali-ligninNaHCO327.7>100.280.12>35.7>83.3100
PBS19.1>101.81.4>5.6>7.1106
Dealkali-ligninNaHCO340.67>100.560.13>17.9>76.9102
PBS30.3>10-----
Humic acidNaHCO328.5>100.60.34>16.7>29.4100
PBS47.6>10-----
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Fukuchi, K.; Koshikawa, T.; Asai, D.; Inomata, M.; Sakagami, H.; Takemura, H.; Kanamoto, T.; Aimi, H.; Kikkawa, Y. Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses. Medicines 2021, 8, 56. https://doi.org/10.3390/medicines8100056

AMA Style

Fukuchi K, Koshikawa T, Asai D, Inomata M, Sakagami H, Takemura H, Kanamoto T, Aimi H, Kikkawa Y. Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses. Medicines. 2021; 8(10):56. https://doi.org/10.3390/medicines8100056

Chicago/Turabian Style

Fukuchi, Kunihiko, Takuro Koshikawa, Daisuke Asai, Megumi Inomata, Hiroshi Sakagami, Hiromu Takemura, Taisei Kanamoto, Hikaru Aimi, and Yuji Kikkawa. 2021. "Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses" Medicines 8, no. 10: 56. https://doi.org/10.3390/medicines8100056

APA Style

Fukuchi, K., Koshikawa, T., Asai, D., Inomata, M., Sakagami, H., Takemura, H., Kanamoto, T., Aimi, H., & Kikkawa, Y. (2021). Lignosulfonate Rapidly Inactivates Human Immunodeficiency and Herpes Simplex Viruses. Medicines, 8(10), 56. https://doi.org/10.3390/medicines8100056

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop